Remunity

Small, discreet pump helping to simplify delivery of Remodulin and fits in your pocket Remunity subcutaneous pump wireless remote

Shown: Wireless remote

COMING SOON: Remunity™ Pump for Remodulin® (treprostinil) Injection

Small

Remunity is 2" in diameter, 3/4" thick, and weighs only 1.7 ounces. It easily fits on a belt or in a pocket and is programmed wirelessly by a separate, small remote.

Simple

Prefilled Remodulin cassettes are shipped to patients by a Specialty Pharmacy. Each cassette contains up to 3 days (72 hours) of medication. Patients simply prime the cassette, twist to lock it to their pump, and go.

Safe

First-of-its-kind acoustic volume-sensing technology1 within a closed-loop system provides continuous, accurate dose delivery of Remodulin. A special internal chamber fills, measures, and verifies the intended dose.

Informative video about the benefits of REMUNITY

Remunity Announcement

Learn more about the latest pump offering for Remodulin.

REMUNITY AVAILABILITY

News Update: February 2020

United Therapeutics and DEKA Research & Development Corp. proudly announce the clearance of the Remunity Pump for Remodulin by the US Food and Drug Administration (FDA). Launch preparations are underway with the anticipated timeline of later this year.

Remunity is a discreet, subcutaneous delivery system designed for adults (age 22 years and greater) with pulmonary arterial hypertension (PAH). The cassettes, which contain enough drug for up to 3 days (72 hours), arrive from the Specialty Pharmacy prefilled, eliminating the need for the patient to mix or fill. Remunity is small, water resistant, and programmed using a wireless remote making it safe and simple to use.

Remunity is the latest advancement from United Therapeutics to improve treatment options for PAH patients.

More information about United Therapeutics, DEKA, and Remunity may be found here.

For Important Safety Information on Remunity, please click here.

Back To Remodulin Pump Systems

View Cadd-Legacy® 1

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Reference: 1. Data on file. United Therapeutics Corporation. Research Triangle Park, NC.